Michael Horberg, MD, MAS, FACP, FIDSA

Michael Horberg

Associate Medical Director, Research, Medical Education, Community Health, Medicaid, HIV & STD, Genetics, Transgender Health

Executive Director, Mid-Atlantic Permanente Research Institute
Director HIV/AIDS and STD, Kaiser Permanente and Care Management Institute

301-816-6302
Michael.Horberg@kp.org

Education:

MD, Boston University School of Medicine
MAS, University of California, San Francisco
BA, Boston University
Residency, Categorical Internal Medicine, Michael Reese Hospital/University of Chicago

Academic Affliations:

Professor of Medicine, Kaiser Permanente School of Medicine

Professional Affliations:

Chair, Institute for Public Health Innovation Board of Directors
Chair, Kaiser Permanente National Research Council
Chair, AHIP/CMS HIV and Hepatitis C Quality Measures Working Group
Governing Board Member, Health Care Systems Research Network
Past Chair, HIV Medicine Association
Past President, Gay and Lesbian Medical Association
Fellow, American College of Physicians
Fellow, Infectious Disease Society of America
Member, AcademyHealth

Michael Alan Horberg, MD, MAS, FACP, FIDSA is Associate Medical Director Research, Medical Education, Community Health, Medicaid, Genetics, HIV and STD, Transgender Health of the Mid-Atlantic Permanente Medical Group (MAPMG) and the director of the Mid-Atlantic Permanente Research Institute (MAPRI).  As Associate Medical Director, Dr. Horberg is responsible for all research activities in Kaiser Permanente Mid-Atlantic States (KPMAS), along with undergraduate, graduate, and continuing medical education, including the new internal medicine residency program.  He serves as the medical director for KPMAS Community Health, and is the Medicaid leader for MAPMG, including Chief Medical Officer for Kaiser Permanente Mid-Atlantic States in Maryland Medicaid. Michael leads HIV, STD, and transgender health care efforts in the region, and HIV and STD care program-wide for Kaiser Permanente.  Dr. Horberg leads our Medical Genetics and Genomics strategy for MAPMG and is Executive Sponsor for KPMAS’ Commission on Cancer Accreditation.

Dr. Horberg serves as director of HIV/AIDS program-wide for Kaiser Permanente and as Clinical Lead for HIV/AIDS and STDs for the Care Management Institute.  Dr. Horberg has served on the Presidential Advisory Council on HIV/AIDS, having co-chaired the Access to Care and Improved Outcomes Committee.  Dr. Horberg is a Fellow of the American College of Physicians and the Infectious Disease Society of America (IDSA).  He is Past-Chair of the Board of Directors of the HIV Medicine Association of IDSA.  He presently serves on the IDSA Quality Performance Committee. Dr. Horberg has served as a commissioner of the State of Maryland Natalie M. LaPrade Medical Cannabis Commission.  He is past-president of the national Gay and Lesbian Medical Association.

In his role as Executive Director of MAPRI, Dr. Horberg leads a department of both clinical and data research with over 50 team members.  In his role as MAPMG lead for Medicaid, he is Chief Medical Office for KPMAS’ participation in Maryland Medicaid, as well as helping lead clinical operational efforts in both Maryland and Virginia Medicaid, and serving on the KPMAS Medicaid Executive Committee.

His HIV research interests are health service outcomes for HIV-infected patients (including HIV quality measures and care improvement, and determinants of optimized multidisciplinary care for maximized HIV outcomes), medication adherence issues in these patients, and epidemiology of the disease.  Dr. Horberg serves as the MAPRI principal investigator for the Kaiser Permanente Research Bank (national genomics initiative).  Other research interests include other sexually transmitted diseases and hepatitis.  Dr. Horberg has published over one hundred manuscripts and delivered over one hundred presentations at scientific meetings; all are in peer-reviewed literature or conferences.  He has chaired multiple Expert Panels on HIV-related provider performance measures (including ones sponsored by CMS, NCQA, and IDSA), and has served on NIH and CDC peer-review panels.

Research Interests:

HIV/AIDS:
  • Models of Care
  • HIV Care and Outcomes Quality Metrics
  • Registry Development
  • Pharmaceutical Safety and Comparative Effectiveness
Sexually Transmitted Disease:
  • Gay/Lesbian Health and STI risk
  • Syphilis
Hepatitis:
  • Registry Development
  • Hepatitis Care Quality Metrics

For a full list of publications, please see Dr. Horberg’s Curriculum Vitae.

  1. Althoff K, Wong C, Hogan B, Desir F, You B, Humes E, Zhang J, Jing Y, Modur S, Lee J, Freeman A, Kitahata M, van Rompey S, Mathews WC, Horberg M, Silverberg M, Mayor A, Salters K, Moore R, Gange S for the North American AIDS Cohort Collaboration on Research and Design, “Mind the Gap: Observation Windows to Define Periods of Event Ascertainment in Longitudinal Electronic Medical Record Data,” Annals of Epidemiology, 2019; 33:54-63
  2. Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Althoff KN, Hessol NA, Achenbach CJ, Brooks JT, Gill MJ, Grover S, Horberg M, Li J, Mathews WC, Mayor AM, Patel P, Rabkin CS, Rachlis A, Justice AC, Moore RD, Engels EA, Silverberg MJ, Dubrow R; North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS, “Association of immunosuppression and HIV viremia with anal cancer risk in persons living with HIV in the United States and Canada,” Clinical Infectious Disease, 2019
  3. Lo Re V 3rd, Newcomb CW, Carbonari DM, Roy JA, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg M, Cachay ER, Kirk GD, Hull M, Gill J, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Kim HN; North American AIDS Cohort Collaboration on Research and Design of IeDEA, “Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients,” JAIDS, 2019; Sep 1;82(1):71-8
  4. Derek D. Satre; Amy S. Leibowitz; Wendy Leyden; Sheryl L. Catz; C. Bradley Hare; Hannah Jang; Jennifer O. Lam; Kendall J. Bryant; Constance M. Weisner; Stacy A. Sterling; Michael Horberg; Paul Volberding; Michael J. Silverberg. Interventions to Reduce Unhealthy Alcohol Use among Primary Care Patients with HIV: The Health and Motivation Randomized Clinical Trial. J GEN INTERN MED (2019)
  5. Levy M, Monroe A, Horberg M, Benator D, Molock S, Doshi R, Powers-Happ L, Castel A, on behalf of the DC Cohort Executive Committee, “Pharmacologic Treatment of Psychiatric Disorders and Time with Unsuppressed HIV Viral Load in a Clinical HIV Cohort,” JAIDS, 2019
  6. Satre D, McNeely J, Hare B, Leibowitz A, Volberding P, Weisner C, Silverberg M, Sally S, Anderson A, Horberg M, Levine-Hall T, Flamm J, “Implementing Electronic Substance Use Disorder and Depression and Anxiety Screening and Behavioral Interventions in Primary Care Clinics Serving People with HIV: Protocol for Promoting Access to Care Engagement (PACE) Trial,” Contemporary Clinical Trials, 2019; Sep;84:105833
  7. Zhu Y, Sidell M, Arterburn D, Daley M, Desai J, Fitzpatrick S, Horberg M, Koebnick C, McCormick E, Oshiro C, Young D, Ferrara A, “Racial/Ethnic Disparities in the Prevalence of Diabetes and Prediabetes by Body Mass Index: Patient Outcomes Research to Advance Learning (PORTAL) Multi-Site Cohort of Adults in the US,” Diabetes Care, 2019
  8. Poteat T, Hanna DB, Rebeiro PF, Klein M, Silverberg MJ, Eron JJ, Horberg M, Kitahata MM, Mathews WC, Mattocks K, Mayor A, Rich AJ, Reisner S, Thorne J, Moore RD, Jing Y, Althoff KN; North American AIDS Cohort Collaboration On Research and Design of the International Epidemiology Databases to Evaluate AIDS, “Characterizing the Human Immunodeficiency Virus Care Continuum Among Transgender Women and Cisgender Women and Men in Clinical Care: A Retrospective Time-series Analysis,” Clinical Infectious Disease, 2019
  9. Althoff K, Gebo K, Moore R, Boyd C, Justice A, Wong C, Lucas G, Klein M, Kitahata M, Crane H, Silverberg M, Gill MJ, Mathews W, DuBrow R, Horberg M, Rabkin C, Klein D, Lo Re V, Sterling T, Desir F, Gange S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the US and Canada: a Collaboration of Cohort Studies,” Lancet HIV, 2019; 6(2) e93-e104
  10. Lewis, K. H., Fischer, H., Ard, J., Barton, L., Bessesen, D. H., Daley, M. F., Desai, J., Fitzpatrick, S. L., Horberg, M., Koebnick, C., Oshiro, C., Yamamoto, A., Young, D. R. and Arterburn, D. E. (2019), Safety and Effectiveness of Longer‐Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort. Obesity, 27: 591-602
  11. Hechter R, Horberg M, Weisner C, Campbell C, Contreras R, Chen L, Yarborough JH, Lapham G, Haller I, Ahmedani B, Binswanger I, Kline-Simon A, Satre D, “Healthcare Effectiveness Data and Information Set (HEDIS) Measures of Alcohol and Drug Treatment Initiation and Engagement among People Living with Human Immunodeficiency Virus (HIV) and Patients without an HIV Diagnosis,” Substance Abuse, 2019
  1. HIV Status and Incidence and Outcomes of Heart Failure
    Goal: The overall purpose of this study is to work with our clinical and policy leaders in HIV and CHF care to quantify the risk of congestive heart failure (CHF) among HIV-infected patients, which antiretroviral therapy medications have increased risk for CHF, and which may be protective, as well as develop care patterns for CHF among our HIV-infected patients.
    Funder: National Heart, Lung, and Blood Institute
    Role: Co-Investigator
  2. Terry Beirn CPCRA Clinical Trials Unit: A City-wide DC Cohort of HIV Infected Persons in Care in the District of Columbia (DC Cohort)
    Goal: The overall purpose of this study is to establish a clinic-based city-wide longitudinal cohort that will describe clinical outcomes in outpatients with HIV/AIDS receiving care in Washington, DC, with the goal of improving HIV/AIDS care in DC.
    Funder: National Institute on Drug Abuse
    Role: Site Principal Investigator
  3. North American AIDS Cohorts Collaboration on Research and Design (NA-ACCORD)
    Goal:
    This is the North America response to IeDEA, and for which Kaiser Permanente Northern California participates. It is a collaborative cohort compendium and analysis for purposes of achieving sufficient power to address issues that could not be adequately addressed by single cohorts.
    Funder:
    National Institute of Allergy and Infectious Diseases
    Role: Site Principal Investigator
  4. Kaiser Permanente HIV Quality Improvement and Performance Program
    Goal: We seek to determine quantitative measures of HIV care and outcomes in Kaiser Permanente, which has never been done on a systematic basis in a managed care organization previously.  We seek to then initiate quality improvement programs where we determine there are opportunities for improvement.
    Funder: Care Management Institute/The Permanente Federation/Kaiser Health Plans
    Role: Principal Investigator
  5. Implementing Computerized Substance Use and Depression Screening and Evidence-Based Treatments in an HIV Primary Care Population
    Goal: The purpose of the overall study is to address the important topic of alcohol, smoking and other substance use and comorbidity screening and treatment among HIV-impacted patients. This study represents an important next step in the evolution of our top-quality HIV care in the context of an aging HIV patient population and has important implications beyond the Kaiser Permanente system.
    Funder: National Institute on Alcohol, Abuse and Alcoholism
    Role: Site Principal Investigator
  6. HIV Infection, Use of Tenofovir and Other Antiretrovirals, and Risk of Fatal and Non-Fatal Comorbidities: Cohort study in Kaiser Permanente
    Goal: The purpose of the overall study is to primarily compare the incidence rate of fatal and non-fatal comorbidities in HIV patients with incidence rates among matched HIV-uninfected controls, and HIV-uninfected individuals prescribed PrEP.
    Funder: Gilead, Inc.
    Role: Co-Principal Investigator
  7. COMpAAAS Tripartite: ART-CC, KP, and VA
    Goal: The purpose of the overall study is to participate in a scientific collaboration across three grant partners to assemble data sets, including electronic health record data.  Partners will interpret and disseminate results of the study through conference abstracts and manuscripts.
    Funder: National Institute of Health
    Role: Site Principal Investigator
  8. National Diagnostic Performance Dashboard to Measure and Track Diagnostic Error Using Big Data
    Goal: The goal of this study is to measure and track “missed diagnoses” of sepsis, stroke, and myocardial infarction and display information in ways that can be acted upon to reduce morbidity and mortality.
    Funder: Gordon & Betty Moore Foundation
    Role: Co-Investigator
  9. Kaiser Permanente Research Bank
    Goal: In this study, KP Research Bank aims to recruit 280K members total across all KP regions to increase the overall Research Bank collection to 500K. Members will be consented to provide a biospecimen and complete a survey. This region will participate in the recruitment and other Research Bank-related efforts, including scientific, strategic and operational.
    Funder: Kaiser Permanente Mid-Atlantic Community Benefits
    Role:
    Principal Investigator
  10. KPMAS HIV Registry
    Goal:
    Develop the HIV registry that closely aligns with the other KP regions’ case definitions. This registry will be used to identify populations for potential research studies, clinical trials, and clinical applications as required.
    Funder:
    Kaiser Permanente Mid-Atlantic Community Benefits
    Role:
    Principal Investigator
  11. KPMAS Hepatitis Registries
    Goal:
    Development of the hepatitis B and C registries are critical to ongoing research efforts for KPMA. The hepatitis C registry case finding and registry population is ongoing, with development of hepatitis B and cirrhosis registries next. Both epidemiologic and clinical applications are anticipated.
    Funder:
    Kaiser Permanente Mid-Atlantic Community Benefits
    Role:
    Principal Investigator
  12. KPMAS Sickle Cell Disease Registry
    Goal:
    Develop a sickle cell disease registry that closely aligns with the other KP regions’ case definitions. The registry will be used to facilitate future IRB-approved research based on known cases within the registry, to improve care, and to enhance clinical decision making.
    Funder: Kaiser Permanente Mid-Atlantic Community Benefits
    Role:
    Principal Investigator